TipRanks
Advertisement
Advertisement

CH:GALD Stock Latest News

Jefferies Reiterates Buy on Galderma as Earnings Beat and 2026 Sales Outlook Rise Support Upside; $205 Price Target Unchanged
RatingsJefferies Reiterates Buy on Galderma as Earnings Beat and 2026 Sales Outlook Rise Support Upside; $205 Price Target Unchanged
2M ago
Galderma Buy Rating Reiterated as Nemluvio Momentum Offsets RelabotulinumtoxinA Delay; 12‑Month Price Target Raised to CHF260
PremiumRatings
Galderma Buy Rating Reiterated as Nemluvio Momentum Offsets RelabotulinumtoxinA Delay; 12‑Month Price Target Raised to CHF260
3M ago
Galderma: FDA Manufacturing Setback Seen as Minor, Long-Term Growth Intact; Buy Rating and $205 Price Target Reiterated
PremiumRatings
Galderma: FDA Manufacturing Setback Seen as Minor, Long-Term Growth Intact; Buy Rating and $205 Price Target Reiterated
3M ago
Benjamin Jackson Lifts Galderma Price Target to $205, Reiterates Buy on Limited Reflydess FDA Risk
PremiumRatings
Benjamin Jackson Lifts Galderma Price Target to $205, Reiterates Buy on Limited Reflydess FDA Risk
3M ago
Galderma Buy Rating Reiterated as Strong Growth Outlook Drives Higher Revenue Forecasts; $260 Price Target Maintained
PremiumRatings
Galderma Buy Rating Reiterated as Strong Growth Outlook Drives Higher Revenue Forecasts; $260 Price Target Maintained
5M ago
Galderma: Solid Q1 Outperformance but Limited Upside Keeps Rating at Hold
PremiumRatingsGalderma: Solid Q1 Outperformance but Limited Upside Keeps Rating at Hold
5M ago
Galderma Group AG: Broad-Based Revenue Outperformance and Lower Execution Risk Support Buy Rating
Premium
Ratings
Galderma Group AG: Broad-Based Revenue Outperformance and Lower Execution Risk Support Buy Rating
5M ago
Capitalizing on Emerging Aesthetic Demand: Galderma’s Menopause and GLP‑1 Weight Loss Opportunity Supports Reiterated Buy Rating
Premium
Ratings
Capitalizing on Emerging Aesthetic Demand: Galderma’s Menopause and GLP‑1 Weight Loss Opportunity Supports Reiterated Buy Rating
5M ago
Galderma Group AG: Buy Rating on Resilient Demand, Growth Catalysts, and Undervalued Long-Term Cash Generation
PremiumRatings
Galderma Group AG: Buy Rating on Resilient Demand, Growth Catalysts, and Undervalued Long-Term Cash Generation
6M ago
Sustained Growth and Favorable Risk‑Reward in Injectable Aesthetics Underpin Galderma Buy Rating
PremiumRatings
Sustained Growth and Favorable Risk‑Reward in Injectable Aesthetics Underpin Galderma Buy Rating
6M ago
Galderma: Restylane Contour Label Expansion Strengthens Aesthetics Leadership and Supports Buy Rating
PremiumRatings
Galderma: Restylane Contour Label Expansion Strengthens Aesthetics Leadership and Supports Buy Rating
6M ago
Hold Rating Maintained as Supportive FY26 Guidance Offers Limited Upside Versus High Expectations and Valuation
PremiumRatings
Hold Rating Maintained as Supportive FY26 Guidance Offers Limited Upside Versus High Expectations and Valuation
7M ago
Buy Rating Backed by Strong Q4 Performance, Upgraded Nemluvio Outlook, and Enhanced 2026 Guidance Upside
PremiumRatingsBuy Rating Backed by Strong Q4 Performance, Upgraded Nemluvio Outlook, and Enhanced 2026 Guidance Upside
7M ago
Buy Rating on Galderma: Leading Global Skin‑Health Platform with Diversified Growth and Undervalued Upside
Premium
Ratings
Buy Rating on Galderma: Leading Global Skin‑Health Platform with Diversified Growth and Undervalued Upside
7M ago
Galderma Buy Rating Underpinned by Strengthened CFO Leadership and Strategic Growth Prospects
Premium
Ratings
Galderma Buy Rating Underpinned by Strengthened CFO Leadership and Strategic Growth Prospects
7M ago
Galderma Group AG: Buy Rating Driven by Underappreciated Nemluvio Peak Sales and Pipeline Upside
PremiumRatings
Galderma Group AG: Buy Rating Driven by Underappreciated Nemluvio Peak Sales and Pipeline Upside
8M ago
Galderma Group AG: Buy Rating Reaffirmed with 19% Price Target Increase Amid Strong Nemluvio Growth Projections
PremiumRatings
Galderma Group AG: Buy Rating Reaffirmed with 19% Price Target Increase Amid Strong Nemluvio Growth Projections
9M ago
Strategic Partnership and Stake Increase Drive Positive Outlook for Galderma: Buy Recommendation
PremiumRatings
Strategic Partnership and Stake Increase Drive Positive Outlook for Galderma: Buy Recommendation
10M ago
Galderma Group AG: Promising Growth Outlook and Strategic Expansion Drive Buy Rating
PremiumRatings
Galderma Group AG: Promising Growth Outlook and Strategic Expansion Drive Buy Rating
10M ago
Galderma Group AG: Promising Growth Potential and Strategic Market Positioning Drive Buy Rating
PremiumRatingsGalderma Group AG: Promising Growth Potential and Strategic Market Positioning Drive Buy Rating
11M ago
Galderma Group AG: Strong Q3 Performance Amid Market Challenges, Hold Rating Reflects Balanced Outlook
Premium
Ratings
Galderma Group AG: Strong Q3 Performance Amid Market Challenges, Hold Rating Reflects Balanced Outlook
11M ago
Galderma Group AG: Strong Q3 Performance and Growth Potential Justify Buy Rating
Premium
Ratings
Galderma Group AG: Strong Q3 Performance and Growth Potential Justify Buy Rating
11M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >